UNITED THERAPEUTICS Corp 8-K

What Happened

• United Therapeutics Corporation (UTHR) filed an 8-K reporting that on July 22, 2026 its Board increased to 13 members and appointed Victor Dzau, M.D. as a director. Dr. Dzau will not initially serve on any Board committee. The Company also entered into its standard director indemnification agreement with Dr. Dzau.

Key Details

• Board size increased to 13 members effective July 22, 2026.
• Initial equity awards granted under the 2026 Stock Incentive Plan on July 22, 2026: 380 restricted stock units (RSUs) and 1,190 stock options.
• Pro‑rata awards for the remainder of the 2026–2027 Board service year: 350 RSUs and 1,110 stock options. Awards follow the Company’s standard non‑employee director compensation program disclosed in the Company’s April 29, 2026 proxy.
• Company reported no related-party transactions with Dr. Dzau since the start of the last fiscal year and none currently proposed exceeding $120,000.

Why It Matters

• The filing documents a governance change: a new independent director was added and the board expanded, which investors should note for oversight and leadership composition. The grant of RSUs and stock options reflects UTHR’s standard compensation for new non-employee directors and was disclosed in the company’s proxy; the indemnification agreement is the Company’s standard form. A press release announcing the appointment was furnished with the 8-K.